Sale!
HCG Pregnyl 1500 IU

HCG Pregnyl 1500 IU

 75.00 400.00

HCG Pregnyl 1500 IU consists of a freeze-dried powder for injection. The active ingredient [human chorionic gonadotrophin (hCG)] which is obtained from the urine of pregnant women, has luteinizing hormone (LH) activity.

Clear
Compare

Description

HCG Pregnyl 1500 IU consists of a freeze-dried powder for injection. The active ingredient [human chorionic gonadotrophin (hCG)] which is obtained from the urine of pregnant women, has luteinizing hormone (LH) activity.
An ampoule contains HCG Injection 1500IU
For a full list of excipients,

Pharmaceutical form
Powder for solution for injection. The powder is a white, dry powder or cake.

Therapeutic indications of HCG Pregnyl 1500 IU
In the female
Sterility due to the absence of follicle-ripening or ovulation.
In combination with FSH or HMG, promotion of controlled superovulation in medically assisted reproduction programmes.
In the male
Hypogonadotrophic hypogonadism.
Delayed puberty associated with insufficient gonadotrophic pituitary function.
Sterility in selected cases of deficient spermatogenesis.

Posology and method of administration of HCG Pregnyl 1500 IU
Posology
In the female
Sterility due to the absence of follicle-ripening or ovulation.
HCG Pregnyl 1500 IU – 10,000 IU hCG to induce ovulation, following treatment with an FSH (Follicle Stimulating Hormone) or HMG (Human Menopausal Gonadotrophins) preparation.
In combination with FSH or HMG, promotion of controlled superovulation in medically assisted reproduction programmes.
HCG Pregnyl 1500 IU – 10,000 IU hCG 30 – 40 hours after the last FSH or HMG injection. HCG Injection 1500IUl should not be administered if the following criteria have not been met: at least 3 follicles greater than 17mm in diameter are present with 17ß estradiol levels of at least 3500 pmol/L (920 picogram/ml). Oocyte collection is carried out 32 – 36 hours after the HCG Injection 1500IU.
As luteal phase support, two to three injections of 1,000 to 3,000 IU hCG each may be given within nine days of ovulation or embryo transfer, for example on day 3, 6 and 9 after ovulation induction or embryo transfer.
In the male
Hypogonadotrophic hypogonadism.
500–1,000 IU hCG 2-3 times weekly.
Delayed puberty associated with insufficient gonadotrophic pituitary function.
HCG Pregnyl 1500 IU twice weekly for at least 6 months.
Sterility in selected cases of deficient spermatogenesis.
Usually, 3,000 IU hCG per week in combination with an FSH or HMG preparation.
This treatment should be continued for at least three months before any improvement in spermatogenesis can be expected. During this treatment testosterone replacement therapy should be suspended. Once achieved, the improvement may sometimes be maintained by hCG alone.
Method of Administration
After addition of the solvent to the freeze-dried substance, the solution should be given immediately by intramuscular or subcutaneous injection. Any unused solution should be discarded. Subcutaneous injection may be carried out by patient or partner, provided that proper instruction is given by the physician. Self administration of Pregnyl should only be performed by patients who are well-motivated, adequately trained and with access to expert advice.

Contraindications
• Hypersensitivity to human gonadotrophins or any of the excipients listed in section
.
• Presence of uncontrolled non-gonadal endocrinopathies (e.g. thyroid, adrenal or pituitary disorders).
• Breast, uterine, ovarian tumours.
• Vaginal bleeding of unknown cause.
• Known or suspected androgen-dependent tumours such as testicular tumours, carcinoma of the prostate or mammary carcinoma in males.
• Malformations of the sexual organs incompatible with pregnancy.
• Fibroid tumours of the uterus incompatible with pregnancy.
Special warnings and precautions for use
In the female
• Since infertile women undergoing assisted reproduction, and particularly IVF, often have tubal abnormalities the incidence of ectopic pregnancies might be increased. Early ultrasound confirmation that a pregnancy is intrauterine is therefore important.
• Prior to treating patients for inadequate endogenous stimulation of the gonads, an examination should be performed to exclude anatomical abnormalities of the genital organs or nongonadal endocrinopathies (e.g. thyroid or adrenal disorders, diabetes). Primary ovarian failure should be excluded by the determination of gonadotrophin levels.
• In the pregnancies occurring after induction of ovulation with gonadotrophic preparations, there is an increased risk of abortion and multiplets. Multiple pregnancy, especially high order, carries an increased risk in adverse maternal and perinatal outcomes. The parents should be advised of the potential risks of multiple births before starting treatment.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.